To further our understanding of this mechanism, we found significantly less nuclear c-MYC in tumor tissue derived from Sirt2−/− HCC mice, suggesting that c-MYC is targeted for degradation prior to entering the nuclear compartment where it functions as a transcription factor. The gene discussed is MYC; the disease is neoplasm.